236 related articles for article (PubMed ID: 32454387)
1. Does muscle invasive bladder cancer following pelvic radiotherapy portend worse prognosis? A seer-based study.
Natale C; Leinwand G; Zeineddine F; Silberstein JL; Krane LS
Cancer Treat Res Commun; 2020; 24():100177. PubMed ID: 32454387
[TBL] [Abstract][Full Text] [Related]
2. The characteristics of bladder cancer after radiotherapy for prostate cancer.
Abern MR; Dude AM; Tsivian M; Coogan CL
Urol Oncol; 2013 Nov; 31(8):1628-34. PubMed ID: 22575239
[TBL] [Abstract][Full Text] [Related]
3. Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.
Kozak KR; Hamidi M; Manning M; Moody JS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e197-204. PubMed ID: 22401916
[TBL] [Abstract][Full Text] [Related]
4. Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes.
Mistretta FA; Cyr SJ; Luzzago S; Mazzone E; Knipper S; Palumbo C; Tian Z; Nazzani S; Saad F; Montanari E; Tilki D; Briganti A; Shariat SF; de Cobelli O; Karakiewicz PI
Clin Genitourin Cancer; 2020 Apr; 18(2):129-137.e3. PubMed ID: 32001182
[TBL] [Abstract][Full Text] [Related]
5. Transitional cell carcinoma urinary bladder manifesting as second malignancy following radiotherapy for carcinoma cervix.
Dey S; Philipraj JS;
Indian J Cancer; 2009; 46(1):71-2. PubMed ID: 19282572
[No Abstract] [Full Text] [Related]
6. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
Guo X; Liu M; Hou H; Liu S; Zhang X; Zhang Y; Wu P; Pang C; Wang J
Int J Clin Oncol; 2019 Aug; 24(8):957-965. PubMed ID: 30903422
[TBL] [Abstract][Full Text] [Related]
7. Radiation-induced urothelial carcinoma.
Saito M; Kondo A; Kato T; Kobayashi M; Miyake K
Urol Int; 1996; 56(4):254-5. PubMed ID: 8776826
[TBL] [Abstract][Full Text] [Related]
8. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
[TBL] [Abstract][Full Text] [Related]
9. Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer.
Chin CP; Smith WH; Cesaretti J; Terk M; Garden EB; Araya JS; Palese MA; Stock RG; Buckstein M
Urol Oncol; 2023 Jun; 41(6):296.e9-296.e16. PubMed ID: 36588020
[TBL] [Abstract][Full Text] [Related]
10. Second primary bladder cancer following pelvic irradiation for other malignancies.
Ravi R
J Surg Oncol; 1993 Sep; 54(1):60-3. PubMed ID: 8377508
[TBL] [Abstract][Full Text] [Related]
11. Radical cystectomy in patients previously treated for localized prostate cancer.
Jayram G; Katz MH; Steinberg GD
Urology; 2010 Dec; 76(6):1430-3. PubMed ID: 20381130
[TBL] [Abstract][Full Text] [Related]
12. Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA.
Zaffuto E; Gazdovich S; Leyh-Bannurah SR; Huland H; Abdollah F; Shariat SF; Menon M; Briganti A; Montorsi F; Karakiewicz PI
Int J Urol; 2017 Feb; 24(2):117-123. PubMed ID: 27875858
[TBL] [Abstract][Full Text] [Related]
13. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
14. Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors.
Scrimger RA; Murtha AD; Parliament MB; Venner PM; Hanson J; Houle G; Chetner M
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):23-30. PubMed ID: 11516847
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder.
Daneshmand S; Stein JP; Lesser T; Quek ML; Nichols PW; Miranda G; Cai J; Groshen S; Skinner EC; Skinner DG
J Urol; 2004 Jul; 172(1):81-4. PubMed ID: 15201742
[TBL] [Abstract][Full Text] [Related]
16. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
[TBL] [Abstract][Full Text] [Related]
17. Risk of colorectal cancer among long-term cervical cancer survivors.
Rodriguez AM; Kuo YF; Goodwin JS
Med Oncol; 2014 May; 31(5):943. PubMed ID: 24696219
[TBL] [Abstract][Full Text] [Related]
18. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
19. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of radical cystoprostatectomy in men with bladder cancer infiltrating prostate versus co-existing prostate cancer: a research study.
Bryniarski P; Fryczkowski M; Pawlaczek P; Pliszek K; Prokopowicz G; Kaletka Z; Paradysz A
BMC Urol; 2010 Sep; 10():16. PubMed ID: 20860834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
